Citius Oncology (CTOR) EBITDA (2023 - 2026)

Citius Oncology (CTOR) has 4 years of EBITDA data on file, last reported at -$28.6 million in Q1 2026.

• On a quarterly basis, EBITDA fell 282.98% year-over-year to -$28.6 million in Q1 2026; TTM through Mar 2026 was -$43.5 million, a 55.22% decrease from a year earlier, with the FY2025 full-year figure at -$23.5 million, down 14.34% from the prior year.
• EBITDA for Q1 2026 stood at -$28.6 million, down from -$5.3 million in the prior quarter.
• Over the last five years, EBITDA for CTOR reached as high as -$147922.0 in Q1 2023 and fell as low as -$28.6 million in Q1 2026.
• Historically, EBITDA has averaged -$6.4 million across 4 years, with a median of -$4.8 million in 2025.
• Across the five-year window, EBITDA plunged 6867.44% in 2024 and jumped 64.43% in 2025, its largest moves.
• Year by year, EBITDA stood at -$4.6 million in 2023, then tumbled by 40.45% to -$6.4 million in 2024, then climbed by 17.87% to -$5.3 million in 2025, then slumped by 444.78% to -$28.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$28.6 million in Q1 2026, -$5.3 million in Q4 2025, and -$4.7 million in Q3 2025.